Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.83 |
| ▸ | LMNA | P02545 | 5/20 | 0.83 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.83 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.83 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.83 |
| ▸ | DRD3 | P35462 | 3/20 | 0.83 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.83 |
| ▸ | HRH1 | P35367 | 3/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.83 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.83 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.83 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.83 |
| ▸ | HRH2 | P25021 | 2/20 | 0.83 |
| ▸ | HTR2A | P28223 | 2/20 | 0.83 |
| ▸ | HTR2C | P28335 | 2/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31097126 | 0.98 | LMNA (0.84) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Di(P-Tolyl)(Dimethylaminoethoxy)Methane SCHEMBL29519554 | 0.91 | LMNA (0.71) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL12543374 | 0.91 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL4064 | 0.91 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL25219551 | 0.90 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL9565209 | 0.90 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL29205078 | 0.90 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL17071 | 0.90 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL11795332 | 0.90 | SLC6A2 (0.96) | SLC6A2SLC6A4SLC6A3LMNACHRM2 | |
| Diphenhydramine SCHEMBL10487818 | 0.90 | LMNA (1.00) | SLC6A2SLC6A4SLC6A3LMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014186623-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF A CHAGAS DISEASE | BIOMED VALLEY DISCOVERIES (US) | 2014-11-20 | — | — | WO | claimed |
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | SALEHANI FOAD | 2005-12-22 | — | — | US | claimed |
| US-12403094-B2 | Rheological solid oral composition | THE PROCTER & GAMBLE COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| US-12372536-B2 | Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof | PFIZER INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-11970789-B2 | Filaments comprising an active agent nonwoven webs and methods for making same | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-30 | — | — | US | disclosed |
| US-11964059-B2 | Methods of delivering an oral care active by administering oral care articles comprising a filament | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-23 | — | — | US | disclosed |
| US-11944693-B2 | Method for delivering an active agent | THE PROCTER & GAMBLE COMPANY (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11744812-B2 | Methods of treatment | FIRST WAVE BIO, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230201143-A1 | METHODS OF TREATMENT | FIRST WAVE BIO, INC. | 2023-06-29 | — | — | US | disclosed |
| US-6024976-A | TRANSDERMAL DRUG DELIVERY WITH PRESSURE SENSITIVE ADHESIVE COMPOSITION OF POLYVINYLPYRROLIDONE WITH DRUG IN MULTILAYER PATCH | NOVEN PHARMACEUTICALS, INC. (US) | 2000-02-15 | — | — | US | disclosed |
| WO-1999015210-A2 | BIOADHESIVE COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| US-5719197-A | DRUG DELIVERY | NOVEN PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| WO-1998001134-A1 | ORAL PHARMACEUTICAL COMBINATIONS OF ANTIHISTAMINIC COMPOUNDS AND TERPENOIDS | NOVARTIS CONSUMER HEALTH S.A. (CH) | 1998-01-15 | — | — | WO | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996040084-A1 | COMPOSITIONS AND METHODS FOR USE OF PRESSURE SENSITIVE ADHESIVE TRANSDERMAL DEVICES CONTAINING A BIOADHESIVE HUMECTANT | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040086-A2 | COMPOSITIONS AND METHODS FOR TOPICAL ADMINISTRATION OF PHARMACEUTICALLY ACTIVE AGENTS | NOVEN PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5446070-A | Flexible, finite, bioadhesive, therapeutical agent in solid form | NOVER PHARMACEUTICALS, INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-4228287-A | ANTIHISTAMINES | N.V. KONINKLIJKE PHARMACEUTISCHE FABRIEKEN (NL) | 1980-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282879-A1 | Methods and composition for treatment of migraine and symptoms thereof | HRH3, HRH4, HNMT | SLC6A2 641/4885SLC6A4 558/4885SLC6A3 1630/4885 |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | SLC6A2 1265/4885SLC6A4 1528/4885SLC6A3 1745/4885 |
| US-11964059-B2 | Methods of delivering an oral care active by administering oral care articles comprising a filament | SMCHD1, ACTN1, KRT18 | SLC6A2 4717/4885SLC6A4 4564/4885SLC6A3 4823/4885 |
| US-11744812-B2 | Methods of treatment | ACE2, ACE, SI | SLC6A2 1581/4885SLC6A4 579/4885SLC6A3 1685/4885 |
| US-11970789-B2 | Filaments comprising an active agent nonwoven webs and methods for making same | VCL, KRT18, TPM4 | SLC6A2 3713/4885SLC6A4 3180/4885SLC6A3 3903/4885 |
| US-20230201143-A1 | METHODS OF TREATMENT | ACE2, ACE, SI | SLC6A2 2015/4885SLC6A4 689/4885SLC6A3 2257/4885 |
| US-11944693-B2 | Method for delivering an active agent | ACTB, KRT18, ACTN1 | SLC6A2 2366/4885SLC6A4 3346/4885SLC6A3 3322/4885 |
| US-11793777-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | SLC6A2 1314/4885SLC6A4 1520/4885SLC6A3 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.